TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04091087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crisaborole ointment
Description: crisaborole ointment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: vehicle ointment
Description: vehicle ointment
Study: NCT03458390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyGIeaCare colon irrigation
Description: PillCam COLON for visualization of bowel lining
Study: NCT01117636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)
Description: Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
Study: NCT01686620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro (Humalog)
Study: NCT02363686

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FEES
Description: A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: BSE
Description: Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
Study: NCT05059496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring stretching with Pressure Biofeedback Unit
Description: Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching with Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring stretching with out Pressure Biofeedback Unit
Description: Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching without Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
Study: NCT00562549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-2101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SLx-2101
Study: NCT00847912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, vehicle control
Description: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped.
Study: NCT01617278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan 1
Description: I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Colon
Description: High definition white light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan 2
Description: I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
Study: NCT03434405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SocialMind
Description: SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Description: Treatment as usual delivered by patient's practitioner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic treatment
Description: Treatment as usual delivered by patient's practitioner
Study: NCT04118816

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: overnight polysomnography recording at least six hours

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: overnight polysomnography recording at least six hours

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple sleep latency test
Description: daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple sleep latency test
Description: daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy

Intervention type: OTHER
Intervention: Continuous positive airway pressure
Description: continuous positive airway pressure treatment for sleep-disordered breathing
Study: NCT00820651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diamel
Description: Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and lifestyle counseling
Description: Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with \<10% of saturated fatty acids and protein 14%, and exercise)
Study: NCT01220895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-specific T-cells, single infusion following single positive CMV PCR result
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CMV-specific T-cells, single infusion following single positive CMV PCR result
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Study: NCT06458803

Intervention type: DRUG
Intervention: Eltrombopag
Description: patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.
Study: NCT03382795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR
Description: Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
Study: NCT03286842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
Study: NCT00915681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: 20 mg/kg continuous IV is over 24 hours
Study: NCT04318899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy adapted for adolescents (DBT-A)
Description: DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy - Standard version (DBT)
Description: DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
Study: NCT03724864

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: delivery of snacks
Description: Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: delivery of snacks
Description: Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: delivery of snacks
Description: Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
Study: NCT02797808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Impact of sertraline on functional brain connectivity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Healthy control non-intervention
Study: NCT03048669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement
Description: A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
Study: NCT04089007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOmNI app
Description: In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
Study: NCT04469413

Intervention type: DRUG
Intervention: Paracetamol Infusion
Description: Continuous and Standard Intermittent Boluses Paracetamol Infusion

Intervention type: DRUG
Intervention: Paracetamol Infusion
Description: Continuous and Standard Intermittent Boluses Paracetamol Infusion
Study: NCT04648384

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blend Protein Supplementation
Description: Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise
Description: 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
Study: NCT01816009

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: duration of antibiotic treatment
Description: Used antibiotics already have the AMM in this indication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duration of antibiotic treatment
Description: Used antibiotics already have the AMM in this indication
Study: NCT05272800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectroscopy Bioimpedance Analysis
Description: Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Examination alone
Description: The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
Study: NCT00601068

Intervention type: OTHER
Intervention: Observational
Description: Group of patients with osteochemonecrosis related to oral bisphosphonate use
Study: NCT03659682

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide
Description: subcutaneous, 1.0 mg, weekly, 48 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: subcutaneous, 1.0 mg, weekly, 48 months
Study: NCT01072214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: gw786034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: gw786034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: gw786034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04840160

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: A tart cherry juice intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A tart cherry juice placebo
Study: NCT02057315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELS-M11
Description: One dose of 5% ELS-M11 over 3 bilateral applications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ELS-M11
Description: One dose of 5% ELS-M11 over 3 bilateral applications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose of matching placebo over 3 bilateral applications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of matching placebo over 3 bilateral applications.
Study: NCT04532060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy
Study: NCT01362036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
Study: NCT00921232

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: During a consultation:~* 3 questionnaires (HADS, FRI, CRA)~* and a form for the sociodemographic data
Study: NCT01797211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
Study: NCT02209077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT performed to collect data from the back of the eye
Description: comparative retinal parameters with Spectralis OCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT performed to collect data from the back of the eye
Description: comparative retinal parameters with Spectralis OCT
Study: NCT03938805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy for insomnia
Description: Patients will be provided with psycho education on different cardiovascular diseases, sleep, insomnia, and provided with different behavioral techniques to improve their sleep. The participants in the intervention Group who receives the Internet-based cognitive behavioral therapy program will also have access to support given by a nurse specialized in sleep. A module is given each week during the 9-week intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group receiving 3 weeks internet-based education on sleep hygiene. A module is given each week during the 3 weeks.
Study: NCT00181181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin 80 mg daily for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo daily
Study: NCT04269226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No recruitment maneuver
Description: Usual ventilation procedures will be applied.